Antibody Drug Therapy
Conventional anticancer therapeutics often suffer from lack of specificity, resulting in toxicities to normal healthy tissues and poor therapeutic index. Antibody-drug conjugates (ADCs) constitute a therapeutic modality in which a cytotoxic agent is chemically linked to an antibody (Ab) that recognizes a tumor-associated antigen. The basic strategy underlying ADC technology is to combine the target selectivity of mAbs with the potency of cytotoxic agents, such as certain natural products and synthetic molecules, with the goal of generating therapeutic drugs that are highly efficacious but also safe. The ADC platform currently includes a growing repertoire of cytotoxic payloads, linker technologies and conjugation methods. Two ADCs have recently received FDA approval and more than 30 are in clinical development. This meeting aims to highlight advances in ADC research, clinical development and regulatory perspectives.
- Innovative Antibody drugs in Clinical Trail and Development
- Antibody-drug Conjugate (ADC) Discovery and Development
- Bispecific and Multispecific antibody discovery and development
- Challenges and New Opportunities with Antibody and Protein Drugs
- Novel Antibody and Biologic Drug Targets
Related Conference of Antibody Drug Therapy
5th International conference on Vaccines, Vaccination and Immunization
Antibody Drug Therapy Conference Speakers
Recommended Sessions
- Anti-Cancer Antibodies
- Antibiotics
- Antibiotics used in Industries
- Antibiotics: Advances in Treatment
- Antibiotics: Applications
- Antibiotics: Clinical Trials
- Antibiotics: Infectious Diseases
- Antibiotics: Mechanism of Action
- Antibodies: Infectious Diseases
- Antibodies: Medical Applications
- Antibody Conjugate Therapeutics: Challenge and Potential
- Antibody Drug Therapy
- Antibody Engineering
- Antibody Humanization Technologies
- Auto Immune Antibodies
- Bio therapeutics : Early Analytical Development
- Bio Therapeutics: Novel Formulation and Delivery Approaches
- Cancer Immune therapy
- Emerging Protein Bio Therapeutics
- Immunotherapy and Immune Checkpoints
- Monoclonal Antibody Therapy
- Next-Generation Sequencing(NGS) in Antibody Discovery and Engineering: Overview and Applications
- Protein Engineering and Genetic Engineering
Related Journals
Are you interested in
- Cancer Immunology and Immunotherapy - IMMUNOLOGY 2024 (Spain)
- Cell & Plant Biology - IMMUNOLOGY 2024 (Spain)
- Cell Biology - IMMUNOLOGY 2024 (Spain)
- CELL, ANIMAL & PLANT BIOLOGY - IMMUNOLOGY 2024 (Spain)
- Clinical Immunology & Current & Future Research - IMMUNOLOGY 2024 (Spain)
- Immune System - IMMUNOLOGY 2024 (Spain)
- Immuno informatics & Systems immunology - IMMUNOLOGY 2024 (Spain)
- Immuno-Genetics - IMMUNOLOGY 2024 (Spain)
- Immunogenetics - IMMUNOLOGY 2024 (Spain)
- Immunohistochemistry - IMMUNOLOGY 2024 (Spain)
- Immunology - IMMUNOLOGY 2024 (Spain)
- Immunotherapy - IMMUNOLOGY 2024 (Spain)
- Nutritional Immunology - IMMUNOLOGY 2024 (Spain)
- OncoImmunology - IMMUNOLOGY 2024 (Spain)
- Pediatric and Neonatal Immunology - IMMUNOLOGY 2024 (Spain)
- Reproductive Immunology - IMMUNOLOGY 2024 (Spain)
- Transplantation and Computational Immunology - IMMUNOLOGY 2024 (Spain)
- Vaccines & Immunization - IMMUNOLOGY 2024 (Spain)
- Virology and infectious diseases - IMMUNOLOGY 2024 (Spain)